All In MedTech

Device Trial Radar · NCT07631715

Withings Hypertension Notification Retrospective Study

Validation of the Withings Hypertension Notification Feature (HTNF)

Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

2,500

Planned (sponsor's estimate)

Start

Mar 1, 2026

Primary completion

Jul 2026

Study completion Jul 2026

Sponsor

Lead sponsor
WithingsNot on our public-company list
Sponsor type
Industry
First posted
Jun 8, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This retrospective, non-interventional clinical investigation evaluates the diagnostic performance of the Withings Hypertension Notification Feature (HTNF), a software-only medical device (SaMD) that analyzes demographic, anthropometric, and physiological parameters collected by Withings connected smart scales to identify patterns suggestive of hypertension. Ground-truth blood pressure measurements are obtained concurrently from Withings connected blood pressure monitors.

Conditions

  • Hypertension

Interventions

  • Withings Blood Pressure Monitor (reference)Device

    Ground-truth weekly average systolic and diastolic blood pressure measurements obtained from Withings connected blood pressure monitors (BPM \[WPM02\], BPM+ \[WPM03\], BPM Core \[WPM04\], BPM Connect \[WPM05\]), validated as non-invasive oscillometric blood pressure monitors per ISO 81060-2:2018. Minimum 7 measurements per user-week required.

  • Withings Hypertension Notification Feature (HTNF)Device

    The Withings Hypertension Notification Feature (HTNF) is a software-only medical device (Software as a Medical Device, SaMD) that analyzes demographic, anthropometric, and physiological parameter data opportunistically collected by Withings connected smart scales to identify patterns suggestive of hypertension and provide a notification to the user.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage-Adjusted Sensitivity (Se) of the Withings HTNF AlgorithmTime frame: up to 7 years
  2. Stage-Adjusted Specificity (Sp) of the Withings HTNF AlgorithmTime frame: up to 7 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Withings SA

    Issy-les-Moulineaux, Île-de-France Region, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.